Skip to content
DataLookout
Menu

NCT05044117

Single-agent Capecitabine as Metronomic Chemotherapy in LAHNSCC (CMHN)

StatusUnknown
PhasePhase 3
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 3 versions: 3 with changes below. See every version on ClinicalTrials.gov ↗

  1. Minor Changed Registry marked status Unknown (sponsor has not verified the record since Feb 2022); last known: Recruiting
  2. Notable Trial status: Not Yet Recruiting to Recruitingv3 Show 4 more changesShow less
    • Eligibility criteria expanded, about 2 words
    • Start date changed from estimate of Oct 2021 to Oct 18, 2021
    • Site details revised
    • Collaborators: 8 to 9
  3. Notable Eligibility criteria expanded, about 2 words
    • Secondary endpoints: details revised at 1 of 5 entries
    v2
  4. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Progression-free survival
Timeframe: 2 years

Secondary (5)

Overall survival
Distant failure-free survival
Locoregional failure-free survival
Adverse events
Patient reported quality-of-life score

Arms and interventions

Clinical observationNo intervention

The standard treatment followed by clinical observation.

Metronomic capecitabineExperimental

The standard treatment followed by a maintenance therapy with capecitabine (650 mg/m2 bid, d1-21, q3w) for 1 year.

Drugs: Capecitabine

Sites

1 site in 1 country

  • Sun Yat-sen University Cancer CenterGuangzhou, Guangdong, China